The age-related macular degeneration (AMD) therapy market in the United States is unique because the market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea and Eylea HD, Novartis’s Beovu, and Roche’s Vabysmo—and of ranibizumab biosimilars has been hampered by the availability of Roche’s Avastin (bevacizumab), frequently compounded and prescribed off-label because of its lower price. Competition facing key brands will further intensify with the launch of Optea’s sozinibercept and the potential launch of AbbVie / Regenxbio’s gene therapy ABBV-RGX-314, as well as biosimilars of Eylea that are expected to launch in the near future. In contrast, the market for geographic atrophy (GA) is limited to two therapies that launched in the United States in 2023—Apellis’s Syfovre and Astellas’s Izervay—although the GA pipeline is quite active. This report will help marketers explore how biosimilars could impact access to premium-priced wet AMD brands and how the introduction of the first gene therapy with an anticipated high price may affect the market and understand the market access challenges in the new GA market.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geography: United States
Primary research: Survey of 100 U.S. ophthalmologists; survey of 30 U.S. MCO PDs / MDs
Fingertip formulary: Formulary coverage and restrictions data for wet AMD therapies and Syfovre by commercial plans covering approximately 160.8 million lives and Medicare Part D plans covering 26.0 million lives nationally.
Key drugs covered: Eylea, Lucentis, Beovu, Vabysmo, Susvimo, Avastin, Byooviz, Cimerli, Eylea HD, ABBV-RGX-314, sozinibercept, Syfovre, Izervay
Content highlights:
Reimbursement and contracting.
Access and prescribing.
Opportunities and challenges for emerging therapies.
Disease-specific special topic: the impact of aflibercept biosimilars on the wet AMD therapy market
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.